AbiVax’s Partnering Prospects For MicroRNA-based Drug Boosted By Rheumatoid Arthritis Data

Phase IIa RA Results Build On Ulcerative Colitis Promise

23 Jun 2021

• By Sten Stovall

Now that AbiVax's novel anti-inflammatory ABX464 has demonstrated solid safety and efficacy in rheumatoid arthritis and ulcerative colitis, the French biotech is exploring additional programs in chronic inflammatory indications – and looking for a partner.

AbiVax reported excellent Phase IIa Clinical Safety And Efficacy Results in RA With 50mg ABX464 • Source: Alamy

Abivax S.A.’s lead investigational therapy, ABX464, has shown proof-of-concept Phase IIa trial for rheumatoid arthritis in impressive style, building on the first-in-class anti-inflammatory’s robust performance last month in a Phase IIb study for ulcerative colitis and, the French biotech hopes, putting it in a stronger negotiating position for eventually partnering the product.

AbiVax’s management, led by CEO Hartmut Erlich, made the comments to analysts on 23 June when outlining positive topline Phase...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Metsera’s Amylin Analog Stars In Obesity Phase I

09 Jun 2025

• By Joseph Haas

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.

Merck & Co.’s Enlicitide Poised To Be First Oral PCSK9 Inhibitor To Market

09 Jun 2025

• By Jessica Merrill

The company announced positive data from two Phase III trials testing the cholesterol-lowering medicine.

Sanofi Cements RSV Dominance As Merck & Co. Rival Awaits FDA D-Day

09 Jun 2025

• By Kevin Grogan

The French company will start shipping its blockbuster shortly to meet expected strong demand in the 2025–26 RSV season.

Pipeline Watch: ASCO Dominates Phase III Readouts

09 Jun 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Quick Listen: Scrip’s Five Must-Know Things

09 Jun 2025

• By Ian Haydock

In this week's episode: Sanofi’s Blueprint buy; AstraZeneca’s breast cancer resistance results at ASCO; BMS and BioNTech’s big bispecific deal; Kymera’s Dupixent in a pill; and Degron’s CEO on pipeline and strategy.